When it comes to precious metals, the author of today’s article declares “I favor gold as a long-term investment, but when it comes to trading, silver is my sardine of choice. From a short-term perspective, silver tends to deliver far more price volatility on a percentage basis.” He proceeds to highlight how the correction “cleansed” the market and made silver stronger – and the products he favors to “turbocharge” a position in silver. For more, CLICK HERE.
4 Biotech Stocks Worthy Of Close Attention
When it comes to biotech’s performance over the last several weeks, the author of today’s article notes that “Part of the sector’s rise is undoubtedly attributed to the work toward developing a coronavirus vaccine yet biotech has also become a safe haven of sorts where worried investors park their money during uncertain times.” Against this backdrop, he highlights four biotech stocks that investors may want to pay particularly close attention to. For more, CLICK HERE.
Charting Biotech’s Next Moves
The niche market segment that’s been dominating the attention of active traders over the last several weeks? Biotechnology! So where is biotech likely headed from here? Today’s article looks to provide an answer to this question by looking “at several charts from across the sector and try[ing] to determine how followers of technical analysis will be positioning themselves over the weeks and months ahead.” For more, CLICK HERE.
This Options Trade Could Net A Quick 300% Gain By Taking Advantage Of Financials’ Weakness
Today’s article outlines an options trade that could net a quick 300% gain by taking advantage of one of the weakest sectors in the market today (even before COVID-19 hit): financials. This trade is premised on the belief that “If stocks stay firm for a while longer, it is very unlikely that lagging financials will suddenly start to lead. And if the market faces another big sell-off before finding its ultimate bottom – which we think is the case – chances are that the weakest stocks are going to get hurt the most.” For more, CLICK HERE.
Will The Coronavirus Be Different For This Perennial Disease Outbreak Loser?
As has been the case with many small-cap biotech stocks amid the coronavirus pandemic, traders have gotten excited in recent weeks about the stock examined in today’s article, one which, not that long ago, had fallen to as low as 10 cents per share and appeared to be heading towards bankruptcy. However, the stock in question generated similar excitement during past disease outbreaks, only for that enthusiasm to fade and shares to crash. Could this time be different – or is history likely to repeat? CLICK HERE.
These 25 Struggling Small-Company Stocks Could Surge, Especially If Buyers Swoop In
Some of the best opportunities going forward may be among the worst-performing small-company stocks that have gone public over the last 11 years, advises the chief equity strategist at BTIG. In particular, he is “zeroing in on companies that have a history with private equity or venture capital backers who could look to take advantage by acquiring the company. That would turn around some of that historic poor performance in a hurry.” For 25 struggling small-company stocks he sees as presenting real opportunities, CLICK HERE.
The Massive – And Mysterious – Rally Of The World’s Best-Performing Stock
What’s clear is that, having surged 2,819% in the past 12 months (and 351% so far this year in the face of a market meltdown), this stock is the best-performing stock in the world over the past 12 months among companies with a market value of $1 billion or more. What’s far less clear to traders and investors, however, is why. Not only has this stock seen extremely low trading volumes, but the company in question derives most of its revenue from the unexciting world of fish farming in the United Arab Emirates. For more on this stock’s massive – and mysterious – rally, CLICK HERE.
Top Biotech Stocks For May – Including A High-Risk/High-Reward Play
When it comes to the top biotech stocks to consider buying this month, as identified in today’s article, one has a virtual monopoly in its market and lots of cash. Another doesn’t have a monopoly, doesn’t have lots of cash, and doesn’t even have an approved drug on the market yet! What this small biotech does have, however, “is tremendous growth potential and at least one possible game-changer in its pipeline” – and while it’s the riskiest of the three stocks, it could also be the biggest winner. For more, CLICK HERE.
A Better Way To Play The Earnings Game?
Given the ability of earnings reports to catapult stock prices higher in a short period of time, the authors of today’s article state “It’s no wonder why options traders tend to salivate like Pavlov’s dogs during earnings season.” They acknowledge, however, that playing the earnings game successfully is not easy – which is why they outline what they believe is a better way for individual investors to capitalize on earnings season. For more, CLICK HERE.
Remdesivir’s COVID-19 Success Could Create A Big “Piggyback” Opportunity For This Under-The-Radar Biotech
There is currently only one drug that has demonstrated the potential to be a safe and effective treatment for COVID-19 in clinical trials: Gilead Sciences’ remdesivir. Today’s article, however, highlights a small, under-the-radar biotech with an experimental drug that has shown early promise in fighting COVID-19 when used in combination with remdesivir, reducing the replication of the novel coronavirus to “undetectable levels”. Could this biotech piggyback on Gilead’s success with remdesivir, creating a big opportunity for investors? CLICK HERE.